英文药名: Tnkase(Tenectelplase Injection)
中文药名: 替奈替普酶注射液
生产厂家: Boehringer Ingelheim
药品简介
这是第一个被批准的清除血栓的药物，该药仅须注射1次，5秒钟内吸收，可简化急性 心脏病 的治疗。它的主要成分是TNK酶，1次注射后能迅速清除血栓。
在美国，每年有1，100，000人发生心脏病突发事件，其中约半数人死亡。这主要是由于心脏相应的血管发生阻塞，若在胸闷心悸等症状发生后立即扩张阻塞的血管，则会降低死亡率。
Tenecteplase的主要副作用是颅内出血及中风。
急性心肌梗死(AMI)是病变的冠状动脉并发粥样斑块破裂出血、血管腔内血栓形成，使冠脉闭塞而至引起心肌严重缺血、坏死。现代医学治疗MAI是建立在心梗的发病机制上，即通过静脉注入纤维蛋白溶解药，使内源性纤溶酶原转变为纤溶酶从而由纤溶酶水解形成的纤维蛋白来溶解血块，使冠脉再通。快速冠脉溶栓可限制梗死范围扩大，减少左室功能不良，提高生存率，这一方法已被临床广泛接受。
规格：50mg 1 vial (支)
 |
TNKase® (Tenecteplase)
TNKase® (Tenecteplase) is supplied as a sterile, lyophilized powder in a 50mg vial under partial vacuum. Each 50mg vial of TNKase is packaged with one 10mL vial of Sterile Water for Injection, USP for reconstitution, The B-D® 10mL syringe with TwinPak™ Dual Cannula Device and three alcohol prep pads.
Generic Name for TNKASE
Tenecteplase 50mg/vial; lyophilized pwd for IV inj after reconstitution.
Legal Classification:
Rx
Pharmacological Class for TNKASE
Tissue plasminogen activator (tPA).
Manufacturer of TNKASE
Genentech, Inc.
Indications for TNKASE
To reduce mortality associated with acute myocardial infarction (AMI).
Adult dose for TNKASE
Start treatment soon after onset of AMI symptoms. Give as single IV bolus over 5 seconds. <60kg: 30mg; ≥60kg–<70kg: 35mg; ≥70kg–<80kg: 40mg; ≥80kg–<90kg: 45mg; ≥90kg: 50kg. Max: 50mg.
Children's dosing for TNKASE
Not recommended.
Contraindications for TNKASE
Active internal bleeding. History of cerebrovascular accident. Intracranial or intraspinal surgery or trauma within 2 months. Intracranial neoplasm, arteriovenous malformation, or aneurysm. Bleeding diathesis. Severe uncontrolled hypertension.
Warnings/Precautions for TNKASE
Avoid noncompressible arterial puncture, internal jugular and subclavian venous puncture, IM injections and nonessential handling of patient during treatment. Increased bleeding risk at puncture sites; minimize arterial and venous punctures. Increased risk of complications with recent major surgery, cerebrovascular disease, GI or GU bleeding, recent trauma, hypertension (systolic BP ≥180mm Hg and/or diastolic BP ≥110mm Hg), left heart thrombus, acute pericarditis, endocarditis, hemostatic defects, hepatic dysfunction, pregnancy, hemorrhagic ophthalmic conditions, septic thrombophlebitis, elderly. Pregnancy (Cat.C). Nursing mothers.
Interactions for TNKASE
Increased bleeding risk with heparin, vitamin K antagonists, aspirin, dipyridamole, GP IIb/IIIa inhibitors. May interfere with coagulation tests.
Adverse Reactions for TNKASE
Bleeding, hypersensitivity reactions, cardiogenic shock, arrhythmias, AV block, pulmonary edema, heart failure, cardiac arrest, recurrent MI, myocardial rupture, cardiac tamponade, pericarditis, pericardial effusion, mitral regurgitation, thromboembolism, electromechanical dissociation, nausea, vomiting, hypotension, fever; cholesterol embolism.
How is TNKASE supplied?
Vial—1 (w. diluent, supplies)